Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent (ICF) prior to any screening procedures being performed~* Ability to comply with protocol requirements~* Metastatic histologically confirmed melanoma that is unresectable~* Presence of \> 3 active brain metastases confirmed/evaluated by MRI~* Measurable disease by MRI per iRANO and RECIST 1.1 criteria~* The time between the baseline MRI and the date of registration should not exceed 28 days. Steroid treatment is permissible before brain MRI evaluation but the dose should have been stable for at least 7 days and should be carefully documented~* Patient must agree to the cerebro-spinal fluid (CSF) collections according to the study protocol~* Patients naïve for systemic treatment are eligible~* Patients pretreated with systemic immunotherapy, targeted therapy or chemotherapy are eligible (exception: previous treatment with the combination of CTLA-4 and PD-1 antibodies)~* Patients must have recovered completely from any treatment-related acute toxicity associated with prior therapy~* At least two weeks must have passed since the last systemic anti-cancer treatment~* Patients with prior local therapy of brain metastases are eligible~* Patients may have received irradiation therapies: A) None; B) Whole brain irradiation only, C) Stereotactic irradiation of single or few metastases, D) Combined B+C)~* Screening laboratory values within 14 days prior to registration must meet the criteria: WBC ≥ 2,000/μL, Neutrophils ≥ 1,500/μL, Platelets ≥ 100 x103/μL, Hemoglobin \> 9.0 g/dL, Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min, AST/ALT ≤ 3 x ULN, total bilirubin ≤ 1.5 x ULN (except patients with Gilbert Syndrome, who can have total bilirubin \< 3.0 mg/dL), INR ≤ 1.5~* ECOG Performance Status 0, 1 or 2~* Expected life expectancy of ≥ 3 months~* Males and females ≥ 18 years old~* Negative serum pregnancy test within 24 hours prior to the start of study drug for women of childbearing potential (WOCBP)~* Women must not be breastfeeding~* WOCBP must agree to follow instructions for method(s) of contraception, as indicated in the ICF, throughout the study and for 23 weeks after the last dose of investigational drug~* Males who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception, as indicated in the ICF, throughout the study and for a period of 31 weeks after the last dose of investigational drug. In addition, male patients must be willing to refrain from sperm donation during this time~* Azoospermic males are exempt from contraceptive requirements. WOCBP who are permanently not heterosexually active are also exempt from contraceptive requirements, but must still undergo pregnancy testing as previously described.~* Patients must agree to use at least two methods of contraception, with at least one highly effective method as listed in the ICF~Exclusion Criteria:~* Diagnosed ocular melanoma~* Previous systemic therapy with the combination of CTLA-4 and PD-1 antibodies~* Use of any investigational or non-registered product within the 30 days before registration in the study~* Prior active malignancy within the previous 3 years except locally curable cancers that have been apparently cured, such as: basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix, or breast~* History of organ transplantation~* Active infection requiring systemic therapy~* Active, known or suspected autoimmune disease (exceptions: patients with controlled Type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders not requiring systemic treatment).~* Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity~* Any serious or uncontrolled medical disorders thatmay increase the risk associated with study participation or study drug administration, impair the ability of the patient to receive protocol therapy, or interfere with the interpretation of study results in the opinion of the investigator~* Known substance abuse or psychiatric disorders that would preclude cooperation with tany requirements of the trial~* Legal incapacity or limited legal capacity~* Administration of live, attenuated vaccine within 4 weeks prior to the start of study drug~* Positive test for HBs Ag or HCV antibody~* Known history of a positive test for HIV or known AIDS~* Patients with known allergy or hypersensitivity to any of the study drugs or excipients~* Patients with results of imaging or radiological examinations indicating increased cerebral pressure which would prevent lumbar puncture

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Phase (Type: EXPERIMENTAL): Treatment phase is divided into the Induction Phase and Maintenance Phase. During the induction phase patients are treated with 1 mg/kg nivolumab and 3 mg/kg ipilimumab, during the maintenance phase with nivolumab 3 mg/kg only .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy